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ABSTRACT
Fracture healing is impaired in aged and osteoporotic individuals.
Because adequate mechanical stimuli are able to increase bone
formation, one therapeutical approach to treat poorly healing fractures
could be the application of whole-body vibration, including low-
magnitude high-frequency vibration (LMHFV). We investigated the
effects of LMHFV on fracture healing in aged osteoporotic mice.
Female C57BL/6NCrl mice (n=96) were either ovariectomised (OVX)
or sham operated (non-OVX) at age 41 weeks. When aged to 49
weeks, all mice received a femur osteotomy that was stabilised using
an external fixator. The mice received whole-body vibrations (20
minutes/day) with 0.3 g peak-to-peak acceleration and a frequency
of 45 Hz. After 10 and 21 days, the osteotomised femurs and intact
bones (contra-lateral femurs, lumbar spine) were evaluated using
bending-testing, micro-computed tomography (μCT), histology and
gene expression analyses. LMHFV disturbed fracture healing in aged
non-OVX mice, with significantly reduced flexural rigidity (−81%) and
bone formation (−80%) in the callus. Gene expression analyses
demonstrated increased oestrogen receptor β (ERβ, encoded by
Esr2) and Sost expression in the callus of the vibrated animals, but
decreased β-catenin, suggesting that ERβ might mediate these
negative effects through inhibition of osteoanabolic Wnt/β-catenin
signalling. In contrast, in OVX mice, LMHFV significantly improved
callus properties, with increased flexural rigidity (+1398%) and bone
formation (+637%), which could be abolished by subcutaneous
oestrogen application (0.025 mg oestrogen administered in a 90-day-
release pellet). On a molecular level, we found an upregulation of
ERα in the callus of the vibrated OVX mice, whereas ERβ was
unaffected, indicating that ERα might mediate the osteoanabolic
response. Our results indicate a major role for oestrogen in the
mechanostimulation of fracture healing and imply that LMHFV might
only be safe and effective in confined target populations.
KEY WORDS: Whole-body vibration, LMHFV, Fracture healing,
Oestrogen receptor signalling, Wnt signalling
INTRODUCTION
Because adequate mechanical stimuli increase bone mass and
improve fracture repair (Claes and Heigele, 1999; Ozcivici et al.,
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2010), mechanical intervention therapies, including whole-body
vibration (WBV), are increasingly used to treat osteoporotic bone
loss (Gómez-Cabello et al., 2012). ‘Low-magnitude high-frequency
vibration’ (LMHFV) became of interest because many preclinical
and clinical studies demonstrated its anabolic effects on healthy and
osteoporotic bone (Rubin et al., 2004; Xie et al., 2006; Xie et al.,
2008). LMHFV combines very low accelerations of ≤1 g (g,
gravitational acceleration, 1 g=9.81 m/s2) with a high frequency,
between 20 and 90 Hz, inducing extremely small strains of ~5−10
με (strain magnitude, symbol ε) in bone tissue; considerably less
than the peak strains generated during activity (which are
2000−3000 με) (Xie et al., 2006). Thus it has been proposed that the
mechanical signal driving the osteogenic response of bone cells
might be oscillatory acceleration rather than the distortion of the
bone matrix (Ozcivici et al., 2010). The mechanisms by which cells
recognise and transduce mechanical signals are complex. A network
of molecules are involved in mechanotransduction, including
oestrogen receptor (ER)-mediated pathways and Wnt/β-catenin
signalling (Liedert et al., 2006; Rubin et al., 2006).
Because of its osteoanabolic effects, LMHFV could also be used
to treat poorly healing bone fractures. Delayed or incomplete
fracture repair is a major issue in orthopaedic surgery, with an
incidence of ~10% and a high socioeconomic burden (Tzioupis and
Giannoudis, 2007). In particular, osteoporotic fractures are
frequently associated with complications, which are partially caused
by the decreased regenerative capacity of osteoporotic bone
(Giannoudis et al., 2007). However, whereas most authors agree that
LMHFV has an osteogenic effect during bone remodelling, its
benefit for fracture healing is unclear. Currently, only a few pre-
clinical studies exist, and these report conflicting results
(Komrakova et al., 2013; Leung et al., 2009; Stuermer et al., 2010a).
Recently, we demonstrated that LMHFV provoked anabolic effects
in non-fractured bone, but failed to increase bone formation in
fracture repair in the same individual (Wehrle et al., 2014). In that
study, we used young non-ovariectomised (non-OVX) mice with
high regenerative capacity and oestrogen levels, which poorly
reflects osteoporotic fracture healing. Although evidence indicates
that LMHFV might stimulate fracture repair, particularly in OVX
animals, the underlying mechanism is unclear (Shi et al., 2010).
OVX leads to rapidly decreased oestrogen levels and induces bone
loss both in humans (Aitken et al., 1973) and rodents (Bouxsein et
al., 2005), indicating its crucial role in bone metabolism. Oestrogen
acts through ERα and ERβ, which are expressed in osteoblasts,
osteocytes and osteoclasts, with different ratios for cortical and
trabecular bone, thereby regulating cell activity in a complex fashion
(Hall et al., 2001). ERα is considered the most essential receptor for
mediating oestrogen effects on bone (Börjesson et al., 2013). ERβ
appears to either antagonise ERα actions (‘ying-yang’ theory) or
modulate ERα-driven gene transcription; hence, the ERα:ERβ ratio
might determine the sensitivity of the cell and its biological
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responses to oestrogen (Böttner et al., 2014; Lindberg et al., 2003).
ERs can also be stimulated by mechanical loading (Galea et al.,
2013), with bone adaptation to mechanical loading requiring ERα
(Lee et al., 2003). The number and activity of ERα is regulated by
oestrogen (Jessop et al., 2001). In contrast, ERβ has been proposed
to inhibit bone formation in response to mechanical loading 
(Saxon et al., 2007; Saxon and Turner, 2006). Because bone
mechanoresponsiveness is known to alter under oestrogen
deficiency (Jagger et al., 1996; Järvinen et al., 2003), LMHFV could
provoke differing effects on fracture healing in OVX animals.
Building upon our previous study on young animals (Wehrle et
al., 2014), we investigated the effect of LMHFV on fracture healing
in aged OVX mice compared with non-OVX mice. This study
demonstrated that LMHFV significantly improves fracture healing
in OVX mice but considerably impairs it in non-OVX mice.
Oestrogen supplementation abolished the anabolic effects of
LMHFV in OVX mice, further confirming its crucial role in the
mechanostimulation of fracture repair. The anabolic effects in OVX
mice might be mediated by ERα-driven gene transcription, whereas
the inhibition of bone formation in non-OVX mice appears to
involve signalling through ERβ and inhibition of Wnt/β-catenin
signalling.
RESULTS
OVX-induced impaired fracture healing involves ERβ and
inhibition of Wnt/β-catenin signalling
We first analysed the effect of OVX in aged mice to characterise the
model (Fig. 1A-I). As expected, OVX induced severe uterus atrophy
(Fig. 1A,B) and significantly reduced oestrogen serum levels
(Fig. 1C). OVX also induced an osteopenic phenotype. In the
trabecular bone of the distal femur, the bone volume density (bone
volume over total volume, BV/TV) and trabecular number (Tb.N)
were significantly reduced by ~50% (Fig. 1D-F). Trabecular
parameters in the lumbar vertebrae (L6) were slightly, but not
significantly, influenced [BV/TV: 19±6% OVX, 25±7% non-OVX;
Tb.N: 3±1 mm−1 OVX, 4±1 mm−1 non-OVX; trabecular thickness
(Tb.Th): 63±10 μm OVX, 61±6 μm non-OVX; trabecular spacing
(Tb.Sp): 256±55 μm OVX, 233±62 μm non-OVX; mean±s.d.,
Fig. 1D]. In OVX mice, the cortical thickness (C.Th) in the femoral
diaphysis was diminished by 14% compared with non-OVX
controls (Fig. 1I).
In fracture healing, OVX significantly reduced the flexural
rigidity of the fracture callus (Fig. 2A) and did not alter the total
callus volume (Fig. 2B), but significantly diminished the BV/TV by
91% (Fig. 2C). The micro-computed tomography (μCT) evaluation
was confirmed by histomorphometry (Fig. 2D,E). Significantly
more cartilage (+180%) and fibrous tissue (+44%) were present in
OVX mice callus, indicating impaired endochondral ossification
with a prolonged presence of cartilage residuals (Fig. 2E).
Consistent with these findings, none of the fracture gaps in these
mice were completely bridged with bone, all being categorised as
‘not healed’ with ≤2 bridged cortices (Fig. 2F). In contrast, 62% of
the non-OVX mice were considered as ‘healed’ with ≥3 bridged
cortices at the four assessed locations.
Callus homogenate gene expression analysis demonstrated
significantly upregulated ERβ (Esr2) in the OVX group, whereas
ERα (Esr1) was unchanged (Fig. 2G). These changes were also
apparent at the protein level, as assessed by immunohistochemistry;
more fibroblastic and chondroblastic cells were positively stained
for ERβ in the fracture callus of the OVX group (Fig. 3A).
Tnfrsf11B, encoding osteoprotegerin (OPG), was significantly
decreased, whereas Tnsf11, encoding receptor activator of nuclear
factor κB (NFκB) ligand (RANKL), was significantly upregulated
after OVX (Fig. 2G), indicating increased osteoclast activity.
Furthermore, Sost, encoding sclerostin, an inhibitor of the
osteoanabolic Wnt signalling pathway, was significantly
upregulated. An increased number of sclerostin-positive osteocytes
were observed in the newly formed bone in the OVX mice fracture
callus (Fig. 3B). Simultaneously, β-catenin, a key molecule of
canonical Wnt signalling, was diminished in chondrocytes and
osteoblasts in the OVX mice calluses (Fig. 3C), indicating inhibition
of Wnt/β-catenin signalling. Other established proliferation and
differentiation markers (cmyc, Bglap, Spp1, Col2a1 and Sox9) were
not significantly affected by OVX (Fig. 2G).
LMHFV impaired fracture healing in non-OVX mice but
improved it in OVX mice
Vibration significantly reduced the flexural rigidity of non-OVX
mice callus by 81% compared with the non-vibrated controls
(Fig. 4A), as shown by μCT analysis. LMHFV significantly
diminished BV/TV by 80% compared with non-vibrated controls,
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TRANSLATIONAL IMPACT
Clinical issue
Osteoporosis and the associated impairment in fracture healing are a
major socioeconomic burden. Because adequate mechanical stimuli
increase bone mass and improve fracture repair, mechanical intervention
therapies, including whole-body vibration (WBV), are increasingly used
to treat osteoporotic bone loss. Low-magnitude high-frequency vibration
(LMHFV) became of interest because many pre-clinical and clinical
studies have demonstrated its anabolic effects on healthy and
osteoporotic bone. LMHFV combines very low accelerations of ≤1 g (g,
gravitational acceleration, 1 g=9.81 m/s2) with high frequency (between
20 and 90 Hz) vibrations, which induce extremely small strains (fractional
changes in bone length) of approximately 5−10 με (strain magnitude,
symbol ε) in bone tissue. However, whereas several works have shown
that LMHFV has an osteogenic effect during bone remodelling, the
benefit of this treatment for fracture healing is still unclear. Currently, only
a few pre-clinical studies exist, and they have reported conflicting results.
In order to design vibration protocols that are able to improve age- and
osteoporosis-associated impaired fracture healing, it is necessary to
better understand the molecular mechanisms that underlie LMHFV-
mediated effects.  
Results
The authors of this study used femur osteotomy in aged mice that were
previously subjected to ovariectomy (OVX, which reduced oestrogen
levels) to model osteoporosis. LMHFV significantly improved fracture
healing in OVX mice but considerably impaired it in aged matched non-
OVX mice, indicating a major role of the oestrogen status in the
mechanostimulation of fracture healing. Gene expression analyses of
homogenates from the fracture callus indicated that the anabolic effects
of LMHFV in OVX mice might be mediated by oestrogen receptor α
(ERα)-driven gene transcription, whereas the inhibition of bone formation
in non-OVX mice appeared to involve signalling through ERβ and
inhibition of Wnt/β-catenin signalling (a pathway involved in bone
homeostasis). Oestrogen supplementation abolished the anabolic effects
of LMHFV in OVX mice, further confirming the crucial role of oestrogen
in the mechanostimulation of fracture repair. 
Implications and future directions
Translating the present results into a clinical setting, LMHFV could be an
attractive therapy to stimulate bone healing in osteoporosis-affected
individuals. However, the distinct oestrogen-dependent effects reported
in this study imply that LMHFV might only be safe and effective in elderly
postmenopausal osteoporotic women. To elucidate this, further pre-
clinical studies beyond rodent models are mandatory, and caution must

















whereas callus volume was unaffected (Fig. 4C,B).
Histomorphometry showed that vibration did not significantly alter
callus composition on day 10 (Fig. 4D) but led to significantly less
bone (−70%) and more fibrous tissue (+55%) on day 21 (Fig. 4E).
Consistent with these findings, in the non-OVX mice, none of the
fracture gaps were bridged with bone, whereas 62.5% of animals in
the non-vibrated group were ‘healed’ (Fig. 4F). Analysis of callus
homogenates and immunohistochemistry demonstrated ERβ
upregulation in the callus, whereas ERα was unaffected (Fig. 4G;
Fig. 3A). Furthermore, Tnfrsf11B was significantly downregulated
in the vibrated non-OVX mice. Sost gene expression was
significantly increased, and an increase at the protein level was
confirmed by immunohistochemistry. There were more sclerostin-
positive osteocytes in the callus and also in the adjacent cortex of
the vibrated non-OVX mice (Fig. 3B), indicating diminished Wnt
signalling, further confirmed by decreased β-catenin staining of
chondrocytes and osteoblasts (Fig. 3C).
In contrast, LMHFV in the OVX mice significantly increased the
mechanical performance of the callus (Fig. 5A) and the BV/TV
(+637%) compared with non-vibrated mice (Fig. 5C), whereas the
total callus volume was unchanged (Fig. 5B). Histomorphometry
(Fig. 5D,E) confirmed these results, showing an increased callus
bone content of the vibrated OVX mice on day 21 (Fig. 5E).
Evaluation of the osteotomy gap osseous bridging categorised 50%
of the vibrated OVX mice as healed, whereas no complete cortical
bridging in the non-vibrated group was found (Fig. 5F). On the
molecular level, LMHFV induced slight, but significant,
upregulation of ERα gene (Ers1) expression in the OVX mice callus
(Fig. 5G), with an increase at the protein level confirmed 
by immunohistochemistry. ERα staining was increased in
fibroblasts, chondrocytes and osteoblasts (Fig. 5H). The most
prominent upregulation was that of Bglap, encoding osteocalcin
(Fig. 5G), indicating increased osteogenic differentiation.
Immunohistochemistry of the callus of the non-vibrated OVX mice
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Fig. 1. Effects of OVX on 52-week-old C57BL/6NCrl mice. OVX was performed at an age of 41 weeks. OVX decreased uterus weight and oestrogen serum
levels, and induced an osteopenic phenotype. (A) Images of representative uteri from OVX and non-OVX mice. (B) Uterus weight. n=12. (C) Oestrogen serum
levels determined using E2-ELISA. n=6. (D) Representative μCT sections of the distal femur and the lumbar spine (L6). (E-H) μCT evaluation of trabecular
bone (Tb.) in the distal femur, n=8. (E) Trabecular bone volume/total volume, Tb. BV/TV; (F) trabecular number, Tb.N; (G) trabecular thickness, Tb.Th; (H)

















showed osteocalcin staining mainly in the newly mineralised tissue
along the cortex, whereas in the vibrated OVX mice, osteocalcin
was also present in the cartilaginous areas (Fig. 5I).
Oestrogen supplementation improved fracture healing but
reduced the anabolic effects of LMHFV in OVX mice
Oestrogen supplementation (denoted OVX+E2) reversed the severe
uterus atrophy (Fig. 6A,B) and restored the oestrogen serum levels
(Fig. 6C) of OVX mice to the physiological levels of non-OVX
mice, indicated by dotted lines in Fig. 6. As expected, oestrogen
supplementation also induced an anabolic effect on femoral
trabecular and cortical bone of the OVX mice, with significantly
increased BV/TV, Tb.N and Tb.Th, significantly decreased Tb.Sp
and increased C.Th (Fig. 6D-I). The physiological values of age-
matched non-OVX mice were far exceeded in the trabecular
compartment of the femur (Fig. 1D-H; dotted lines in Fig. 6D-H).
In contrast, oestrogen treatment only slightly affected the trabecular
bone in the lumbar spine (BV/TV: 26±4% OVX+E2, 19±6% OVX;
Tb.N: 4±1 mm−1 OVX+E2, 3±1 mm−1 OVX; TbTh: 71±7 μm
OVX+E2, 63±10 μm OVX; TbSp: 237±49 μm OVX+E2, 256±55
μm OVX; mean±s.d.; Fig. 6D).
With respect to fracture healing, oestrogen supplementation
significantly improved callus properties compared with oestrogen-
untreated OVX mice (Fig. 7A-H). Flexural rigidity (+1439%) and
BV/TV (+254%) were increased in the oestrogen group (Fig. 7A,C).
Consistent with these findings, 50% of the supplemented mice
displayed complete cortical bridging, whereas most of the non-
supplemented OVX mice were ‘not healed’ (Fig. 7F). Thereby,
supplemented mice almost reached the bridging scores of the non-
OVX mice (Fig 2F; Fig. 7F), suggesting that oestrogen treatment
improved OVX-induced impaired fracture healing.
LMHFV of oestrogen-supplemented OVX mice did not provoke
a positive effect on fracture healing (Fig. 7A-I). Neither flexural
rigidity nor callus composition was significantly altered compared
with non-vibrated oestrogen-supplemented OVX mice (Fig. 7).
Notably, LMHFV considerably reduced cortical bridging compared
with non-vibrated oestrogen-supplemented OVX mice (Fig. 7F). In
conclusion, vibration did not improve fracture healing in oestrogen-
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Fig. 2. Effects of OVX on bone healing 10 and 21 days after osteotomy. OVX significantly impaired fracture healing, increased ERβ expression and
inhibited Wnt/β-catenin signalling. (A) Flexural rigidity (EI) of the fracture callus after 21 days. (B) Total callus volume (TV) as assessed by using μCT. (C) Bone
volume/total volume (BV/TV) as assessed by using μCT. (D) Callus composition on day 10 as assessed by histomorphometry, given as a percentage of the
total callus area. Bone, TOT; cartilage, Cg; and fibrous tissue,  FT. (E) Callus composition on day 21 assessed by histomorphometry. (F) Percentage of mice
with bony bridging of the fracture gap. (G) Gene expression in OVX versus non-OVX mice as assessed by qPCR. The dashed line indicates the level at which
















supplemented OVX mice, but rather counteracted the positive
oestrogen effect.
DISCUSSION
Because of the proposed osteoanabolic effects of whole-body
vibration, we investigated the effect of LMHFV on the OVX-
induced impairment of fracture healing. LMHFV significantly
improved the compromised fracture healing in OVX mice, and this
effect was abolished by external oestrogen application. In OVX
mice fracture callus, vibration significantly upregulated ERα,
whereas ERβ was unaffected, indicating that ERα might mediate the
osteoanabolic response in OVX mice. In contrast, LMHFV
considerably impaired non-OVX mice fracture healing. In the
fracture callus of these mice, vibration increased ERβ and Sost
expression, whereas β-catenin levels were decreased, suggesting that
ERβ might mediate the negative effects by inhibiting osteoanabolic
Wnt/β-catenin signalling.
To characterise our mouse model, we first analysed the effect of
OVX on intact bone and fracture healing. As shown previously
(Bouxsein et al., 2005; Wright et al., 2008), OVX induced an
osteoporotic phenotype with a significant decline in trabecular and
cortical bone properties. This effect was more pronounced in the
femur compared with the lumbar spine. Such site-specific effects are
known and can be explained by local differences in bone metabolic
activity (Bouxsein et al., 2005; Liu et al., 2014). In agreement with
our own previous data (Beil et al., 2010) and other studies
(Namkung-Matthai et al., 2001; Oliver et al., 2013), fracture healing
was considerably disturbed after OVX through impaired
intramembranous and endochondral bone formation. On the
molecular level, we, like others (He et al., 2011), found upregulated
callus ERβ mRNA and protein levels, whereas ERα expression was
unaffected by OVX. Chondroblasts in particular stained intensively
for ERβ, indicating that ERβ signalling might play a role in the
prolonged persistence of cartilage residuals. This is supported by the
accelerated endochondral ossification and improved bone healing in
ERβ-null mice (He et al., 2012).
The ER and Wnt signalling pathways interact at various levels in
regulating bone homeostasis (Baron and Kneissel, 2013). ERs
regulate Sost expression (Bhukhai et al., 2012; Galea et al., 2013),
the gene encoding sclerostin, a negative regulator of osteoblast
activity produced by osteocytes. Sclerostin antagonises Wnt binding
to its low-density lipoprotein receptor-related protein-5 and -6 co-
receptors, thereby inhibiting Wnt/β-catenin signalling and osteoblast
activity (Semenov and He, 2006). Notably, we observed upregulated
Sost expression and more sclerostin-stained osteocytes in the
fracture callus, indicating Wnt signalling inhibition, which was
further corroborated by the reduced β-catenin immunostaining in
chondrocytes and osteoblasts. Because Wnt/β-catenin signalling is
crucial for bone formation and fracture healing (Baron and Kneissel,
2013), its inhibition might play an important role in the
pathomechanisms of impaired healing following OVX. In agreement
with these results, we observed increased Tnfsf11 expression,
encoding for RANKL, a stimulator of osteoclast activity, but a
downregulation of Tnfrsf11b, a target gene of canonical Wnt
signalling encoding the RANKL antagonist OPG (Glass et al.,
2005). The altered OPG:RANKL ratio in the fracture callus of OVX
mice accounts for increased osteoclast activity, which has been
described by others in OVX-associated impaired fracture healing
(Chung et al., 2012). The expression of other well-established
osteogenic (Bglap and Spp1) and chondrogenic (Col2a1 and Sox9)
markers were unaffected. Nevertheless, our data indicate that an
altered ERα:ERβ expression ratio might contribute to the bone
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Fig. 3. Representative immunohistological images of the periosteal fracture callus. Upper row, non-vibrated non-OVX mouse; middle row, vibrated non-

















healing impairment after OVX through inhibition of Wnt/β-catenin
signalling.
We have previously demonstrated that LMHFV moderately
reduces bone formation in the fracture callus of 12-week-old non-
OVX mice (Wehrle et al., 2014) when using a vibration protocol that
was osteoanabolic in the intact mouse skeleton (Xie et al., 2006).
Here, we demonstrated that vibration was even more harmful in
aged non-OVX mice. Vibration strongly inhibited bone formation
and impaired the mechanical competence of the callus, while the
fracture gap was not bridged with bone. Interestingly, on the
molecular level, the vibration-induced effects were similar to those
induced by OVX. Vibration led to upregulated ERβ gene expression
in the callus of the non-OVX mice, confirmed using
immunostaining, whereas ERα expression was unaffected. The
expression of ERs is regulated by mechanical stimuli (Lau et al.,
2006; Zaman et al., 2010), and ERs regulate load-induced bone
adaptation in a complex manner involving both ligand-dependent
and -independent mechanisms (Galea et al., 2013). Evidence
suggests that ERα and ERβ might have opposing effects in
mechanotransduction. Because mechanically induced periosteal
bone formation is more effective in female ERβ-null mice, it has
been suggested that ERβ might inhibit bone formation in response
to mechanical loading (Saxon et al., 2007; Saxon and Turner, 2006).
Moreover, low-dose oestrogen treatment suppresses periosteal bone
formation in response to mechanical loading (Saxon and Turner,
2006). In contrast, signalling through ERα mediates anabolic effects
in mechanotransduction (Jessop et al., 2001; Lee et al., 2003; Saxon
and Turner, 2005). Therefore, we suggest that the vibration-induced
ERβ increase might account for the inhibited bone formation in non-
OVX mice fracture calluses. Furthermore, ER and Wnt signalling
have been shown to interact during mechanotransduction (Galea et
al., 2013; Liedert et al., 2010). This was confirmed in our model by
the increase in ERβ, which was associated with a significant
upregulation of Sost and a decrease in β-catenin, indicating
inhibition of osteoanabolic Wnt/β-catenin signalling, similar to that
in OVX-induced impaired fracture healing.
Notably, vibration had contrasting effects in aged-matched OVX
mice, whereby LMHFV significantly improved fracture healing
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Fig. 4. Effects of LMHFV on bone healing in non-OVX mice at 10 and 21 days after osteotomy. LMHFV significantly impaired fracture healing, increased
ERβ expression and inhibited Wnt/β-catenin signalling. (A) Flexural rigidity (EI) of the fracture callus after 21 days. (B) Total callus volume (TV) as assessed by
μCT. (C) Bone volume/total volume (BV/TV) as assessed by μCT. (D) Callus composition on day 10 as assessed by histomorphometry, given as a percentage
of the total callus area. Bone, TOT; cartilage, Cg; and fibrous tissue, FT. (E) Callus composition on day 21 as assessed by histomorphometry. (F) Percentage of
mice with bony bridging of the fracture gap. (G) Gene expression in vibrated non-OVX mice versus non-vibrated non-OVX mice as assessed by qPCR. The
















compared with non-vibrated OVX mice. Our results confirm, at
least in part, those in a previous report showing that LMHFV did not
have any effect in older non-OVX rats but improved bone healing
in aged-matched OVX rats (Shi et al., 2010). Those authors
speculated that, in bone healing, low oestrogen levels might be
associated with high mechanosensitivity and that an altered
expression of ERs might mediate the LMHFV effects. Our
molecular data support this assumption. ERβ expression in the
fracture callus, which was enhanced both by OVX and vibration
compared with non-OVX mice, was not further increased in vibrated
OVX animals. In contrast, ERα expression was significantly
upregulated in the callus homogenates, as visualised by
immunostaining. Taken together, in the absence of oestrogen,
vibration induced a shift in the ERα:ERβ ratio, which could account
for the improved bone healing, due to the above-mentioned
proposed opposing effects of both receptors in mechanotransduction
(Jessop et al., 2001; Saxon et al., 2007; Saxon and Turner, 2005;
Saxon and Turner, 2006). We also observed significant upregulation
of osteocalcin mRNA and protein, indicating enhanced osteoblast
differentiation.
To confirm the crucial role of oestrogen in the distinct vibration-
induced effects in non-OVX and OVX mice, we supplemented
oestrogen using subcutaneous 17β oestrogen pellets. We
hypothesised that, if oestrogen was a key player in the
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Fig. 5. Effects of LMHFV on bone healing in OVX mice 10 and 21 days after osteotomy. LMHFV significantly improved fracture healing and increased
ERα (Esr1) and Bglap expression. The dashed lines indicate the values of aged-matched non-OVX mice. (A) Flexural rigidity (EI) of the fracture callus after 21
days. (B) Total callus volume (TV) as assessed by μCT. (C) Bone volume/total volume (BV/TV) as assessed by μCT. (D) Callus composition on day 10 as
assessed by histomorphometry, given as a percentage of the total callus area. Bone, TOT; cartilage, Cg; and fibrous tissue, FT. (E) Callus composition on day
21 as assessed by histomorphometry. (F) Percentage of mice with bony bridging of the fracture gap. (G) Gene expression in vibrated OVX versus non-vibrated
OVX mice as assessed by qPCR, n=6. The dashed line indicates the level at which there is no difference in expression. (H,I) Representative
immunohistological images of the periosteal fracture callus of non-vibrated and vibrated OVX mice. Immunostaining for ERα (H) and osteocalcin (I). Scale

















mechanostimulation of fracture healing, it would abolish or at least
diminish the positive LMHFV effects. Although oestrogen treatment
returned uterus weight and oestrogen serum levels to physiological
values, the OVX-induced bone loss was overcompensated, at least
in the trabecular bone of the distal femur. Trabecular number and
thickness were significantly increased, exceeding that of aged non-
OVX and young mice (unpublished data). It has also been
demonstrated by others that external oestrogen application does not
completely reverse the physiological bone status in mice (Lane et
al., 1999; Modder et al., 2004; Otto et al., 2012), which might be a
limitation of this model. As expected from the literature (Kolios et
al., 2010; Stuermer et al., 2010b), oestrogen treatment improved the
OVX-induced compromised fracture healing. Bending stiffness,
callus volume, bone formation and bony bridging of the fracture gap
significantly increased, and the cartilage fraction decreased,
although healing did not reach the level of age-matched non-OVX
mice. As hypothesised, LMHFV did not further improve fracture
healing in the oestrogen-supplemented OVX mice. Healing
parameters remained below non-OVX controls, whereas in OVX
mice without oestrogen supplement, vibration fully compensated for
compromised fracture healing. Taken together, these results confirm
the key role of oestrogen in the vibration-induced effects on fracture
healing.
Taken together, LMHFV disturbed fracture healing in aged mice
but improved it in age-matched OVX mice, indicating that the
oestrogen status plays a major role in the mechanostimulation of
fracture healing. Our molecular results imply that the LMHFV-
induced osteoanabolic effects in OVX mice might be mediated by
ERα-regulated gene transcription, whereas ERβ signalling might be
responsible for inhibited bone formation in vibrated non-OVX mice.
Transferring the present results to a clinical setting, LMHFV would
be an attractive therapy to stimulate bone healing in osteoporotic
patients. However, the distinct oestrogen-dependent effects imply
that LMHFV might only be safe and effective in elderly
postmenopausal osteoporotic women. Further pre-clinical studies
beyond rodent models are mandatory, and caution must be paid in
clinical trials to restrict application of the technique to suitable
patients.
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Fig. 6. Effects of oestrogen (E2) supplementation on 52-week-old OVX mice. OVX and E2 pellet implantation were performed at an age of 41 weeks. E2
increased uterus weight and oestrogen serum levels, and reversed the osteopenic phenotype of non-supplemented OVX mice. The dotted lines indicate the
values of aged-matched non-OVX mice. (A) Images of representative uteri. (B) Uterus weight. n=7-12. (C) Oestrogen serum levels determined using E2-
ELISA. n=6. (D) Representative μCT sections of the distal femur and the lumbar spine (L6). (E-H) μCT evaluation of trabecular bone (Tb.) in the distal femur.
n=8. (E) Trabecular bone volume/total volume, Tb. BV/TV; (F) trabecular number, Tb.N; (G) trabecular thickness, Tb.Th; (H) trabecular spacing, Tb.Sp; and (I)


















All animal experiments were performed in compliance with the guide for
the care and use of laboratory animals (National Research Council, 2011)
and were approved by the local ethical committee (No. 1026 and 1113,
Regierungspräsidium Tübingen, Germany). Female C57BL/6NCrl mice
(n=96) were purchased from Charles River (Sulzfeld, Germany). The mice
received a standard mouse feed (ssniff® R/M-H, V1535-300, Ssniff, Soest,
Germany). At 2 weeks prior to OVX, the diet of the respective animals 
was changed to a phytooestrogen-reduced chow (ssniff® R/M-H
Phytooestrogenarm, Ssniff).
Study design
The mice were randomly assigned to six groups (Table 1). At age 41 weeks
the mice were either bilaterally ovariectomised (OVX, groups 3−6) or sham-
operated (non-OVX, groups 1 and 2). Immediately after OVX, subcutaneous
17β oestrogen pellets (0.025 mg per pellet, 90 day-release; Innovative
Research of America, Sarasota, FL) were implanted in a subset of 16 mice
(groups 5 and 6). When aged 49 weeks, all mice received a femur osteotomy
and were randomly assigned to non-vibrated control (non-LMHFV) or
treatment groups (LMHFV) (Table 1). The treatment groups received
LMHFV as described below. The mice were killed at 10 (n=5-7 in groups
1-4) or 21 days (n=8 in groups 1-6) after surgery. Intact bones (contra-lateral
femurs, lumbar spine) and the osteotomised femurs were evaluated using
biomechanical testing, μCT and histomorphometry. On day 10, callus
homogenates of groups 1-4 (n=6) were used to assess gene expression using
a quantitative polymerase chain reaction (qPCR).
Femur osteotomy
Surgery was performed as described previously (Wehrle et al., 2014).
Briefly, a 0.4-mm osteotomy gap was created at the mid-shaft of the right
femur and stabilised using an external fixator (axial stiffness 3 N/mm,
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Fig. 7. Effects of LMHFV and oestrogen (E2) supplementation on bone healing in OVX mice 21 days after osteotomy. The dotted lines indicate the
values of aged-matched non-OVX mice. E2 supplementation of OVX mice significantly improved fracture healing. Additional LMHFV did not further increase
bone healing. Physiological values of aged-matched non-OVX mice were not achieved. (A) Flexural rigidity (EI) of the fracture callus after 21 days. (B) Total
callus volume (TV) as assessed by μCT. (C) Bone volume/total volume (BV/TV) assessed using μCT. (D) Callus composition on day 10 assessed by
histomorphometry, given as a percentage of the total callus area. Bone, TOT; cartilage, Cg; and fibrous tissue, FT. (E) Callus composition on day 21 as
assessed by histomorphometry. (F) Percentage of mice with bony bridging of the fracture gap. (G-I) Representative histological sections of fractured femurs 21
days after osteotomy stained using Giemsa. (G) non-vibrated OVX mouse, (H) non-vibrated OVX mouse with E2 supplementation, (I) vibrated OVX mouse

















RISystem, Davos, Switzerland). Preoperatively, all mice received a single
dose of antibiotic (clindamycin-2-dihydrogenphosphate, 45 mg/kg of body
weight, Clindamycin, Ratiopharm, Ulm, Germany). Analgesia (25 mg/l,
Tramal®, Gruenenthal GmbH, Aachen, Germany) was provided through the
drinking water 2 days before and 3 days after surgery.
LMHFV treatment
LMHFV was applied using custom-made vibration platforms as described
previously (Wehrle et al., 2014). Starting on the third postoperative day, the
mice were placed on the platforms for 20 minutes per day for 5 days per
week and received vertical vibration with 0.3 g peak-to-peak acceleration
(apeak-to-peak) and a frequency (f) of 45 Hz. Controls were sham vibrated.
Biomechanical testing
The mechanical properties of intact and osteotomised femurs explanted on
day 21 were investigated using a non-destructive three-point bending test
and flexural rigidity was calculated as described previously (Wehrle et al.,
2014).
μCT
On day 21, femurs and lumbar vertebrae were scanned in a μCT device
(Skyscan 1172, Kontich, Belgium) at 8 μm resolution using a voltage of 
50 kV and 200 μA. Calibration and global thresholding (641.9 mg
hydroxyapatite/cm3 for callus and cortical bone; 394.8 mg hydroxyapatite/cm3
for trabecular bone) was performed as described previously (Wehrle et al.,
2014). Non-fractured femurs [trabecular volume of interest (VOI): 90 slices
of 8-μm thickness in distal femur; cortical VOI: 250 slices of 8 μm], lumbar
spine (trabecular bone: spherical VOI, d=0.8 mm) and the osteotomy gap were
evaluated. Common ASBMR standard parameters were determined
(Dempster et al., 2013). According to the standard clinical evaluation of X-
rays, the number of bridged cortices per callus was evaluated in two
perpendicular planes (Data viewer, Skyscan, Kontich). A ‘healed fracture’ was
considered to have ≥3 bridged cortices per callus.
Histomorphometry
The bone specimens were embedded in paraffin (day 10) or methyl
methacrylate (day 21). Safranin O (day 10; n=5-7 per group) or Giemsa (day
21; n=8 per group) staining was performed on longitudinal sections of the
fracture calli. In the region of interest (ROI), the relative amounts of newly
formed bone (TOT), cartilage (Cg) and fibrous tissue (FT) were determined
using image analysis (Leica DMI6000 B; Software MMAF Version 1.4.0
MetaMorph®; Leica, Heerbrugg, Switzerland). On day 10, the periosteal
callus between the inner pins of the fixator and on day 21 the osteotomy gap
was defined as the ROI (Wehrle et al., 2014).
Immunohistochemistry
Immunohistochemical staining for ERs (ERα: sc-542; ERβ: sc-8974, Santa
Cruz Biotechnology, Dallas, TX), sclerostin (AF1589, R&D Systems,
Minneapolis, MN), osteocalcin (orb 77248, Biorbyt Ltd, Cambridge, UK)
and β-catenin (06-734, Merck Millipore, Billerica, MA) was performed on
paraffin-embedded sections after deparaffinisation using xylene and
rehydration using methanol. After blocking nonspecific sites [ERα and ERβ:
phosphate-buffered saline (PBS) + 10% goat serum; sclerostin: PBS + 10%
horse serum; osteocalcin: tris-buffered saline (TBS)-Triton X-100 + 5% goat
serum; β-catenin: 4% BSA + 0.1% Triton X-100] for 60 minutes at room
temperature, the sections were incubated with the primary antibody against
ERα (1:75 in PBS + 2% goat serum), ERβ (1:40 in PBS + 1% goat serum),
sclerostin (1:200 in PBS + 1% horse serum), osteocalcin (1:200 in TBS-
Tween 20 + 1% goat serum) or β-catenin (1:150 in PBS + 1% BSA + 0.1%
Triton-X) overnight at 4°C. To detect the primary antibody, either a
secondary biotinylated goat anti-rabbit-IgG antibody (Invitrogen, Life
Technologies Corporation, Darmstadt, Germany; for ERα, ERβ, osteocalcin
and β-catenin) or a donkey anti-goat-IgG antibody (Invitrogen, Life
Technologies Corporation; for sclerostin) was added for 30 minutes at room
temperature. For signal amplification, the slides were incubated either with
streptavidin-conjugated horseradish peroxidase (Zytomed Systems, Berlin,
Germany) for 15 minutes (ERα, sclerostin and β-catenin) or avidin-biotin
complex (Vector, Burlingame, CA) for 30 minutes (ERβ and osteocalcin).
Chromogen AEC Single Solution (Zytomed) or NovaRed (Vector) was used
as the detection substrate. Counterstaining was performed using hematoxylin
(Waldeck, Münster, Germany). Species-specific IgG was used as isotype
control in an additional section of each sample.
Gene-expression analysis in the fracture callus
On day 10, fractured femurs (n=6 per group) were snap-frozen in liquid
nitrogen and stored at −80°C. The callus between the inner pins, including
marginal cortical bone, was excised and pulverised in a vibration mill at 30
Hz for 2.5 minutes. After adding 1 ml Trizol, the samples were centrifuged
at 5000 g for 30 seconds and callus RNA was isolated using the RNeasy-
Mini-Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions, including a DNase digestion step. The RNA was eluted in 30
μl RNase-free water and stored at −80°C. Extracted RNA concentration and
integrity were verified using 260 nm spectrophotometry with the reference
wavelengths 280 and 230 nm and agarose gel electrophoresis. Reverse
transcription of 1 μg of RNA was performed using the Omniscript RT kit
(Qiagen). The PCR reaction mixture (12.5 μl SYBR Green MasterMix, 0.25
μl ROX, 0.1 µM forward primer and 0.1 µM reverse primer, 8.25 μl RNase-
free water and 2 μl cDNA) was prepared and each sample was tested in
duplicates using an Abi StepOne Plus Cycler (Applied Biosystems,
Darmstadt, Germany) using the following cycling conditions: 50°C for
2 minutes, 95°C for 2 minutes, 40 cycles each consisting of 95°C for
15 seconds and 60°C for 1 minute (see supplementary material Table S1 for
primer sequences). Then, melting curve acquisition was performed (95°C
for 15 seconds, 60°C for 1 minute, 95°C for 15 seconds). Data were
analysed using the ΔΔCt method. Ct values obtained for each sample 
were normalised to those for the house-keeping gene GAPDH;
ΔΔCt=ΔCt(treatment group) – ΔCt(control group) was calculated and a fold-
change in gene expression of the treatment group versus the control group
was expressed as 2–ΔΔCt.
Oestrogen serum levels
Oestrogen serum levels were determined (n=6 per group and time point)
using a competitive ELISA kit (Oestradiol ELISA, Calbiotech, Spring
Valley, CA) with a detection limit of 3.94 pg oestrogen/ml serum.
Statistical analysis
Sample size was calculated based on previous studies (Wehrle et al., 2014)
for two main outcome parameters: flexural rigidity in fractured femurs and
trabecular BV/TV in non-fractured femora (power, 80%; alpha, 0.05).
Results are presented as the mean ± s.d. Data were tested for normal
distribution (Shapiro-Wilk normality test) and homogeneity of variance
(Levene test). Dependent on the test outcome, a comparison of either non-
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Table 1. Study design
Group number Group name Ovariectomy E2 pellet Osteotomy Vibration (LMHFV) Number of mice
1 Non-OVX non-LMHFV – – + – n=19
2 Non-OVX LMHFV – – + + n=21
3 OVX non-LMHFV + – + – n=21
4 OVX LMHFV + – + + n=20
5 OVX+E2 non-LMHFV + + + – n=8
6 OVX+E2 LMHFV + + + + n=8
















OVX versus OVX, OVX versus OVX+E2 or non-LMHFV versus LMHFV
groups was made using a Student’s t-test (normally distributed data with
homogenous variance) or the Mann–Whitney U-test (data either not
normally distributed and/or not showing homogenous variance; IBM SPSS
Statistics Version 19). The level of significance was set at P≤0.05.
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